Latest Headlines

Latest Headlines

Qiagen backs liquid biopsy startup Exosome in $60M Series B

Diagnostics giant Qiagen has joined the syndicate of Exosome Diagnostics--helping to distinguish this liquid biopsy startup from its growing crowd of peers. The pair are already partnered under a 2014 lung cancer diagnostic development deal. The Cambridge, MA-based startup has raised a $60 million Series B round to launch its liquid biopsy test via its CLIA-certified lab as well as to seek out companion diagnostics deals with biopharmas.

NC State team: Gold nanoparticles can control the shape of DNA, RNA

DNA and RNA hold a supercomputer's worth of information in a very small space in the nucleus of a cell. And how they are packed so tightly in such a tight volume can offer new ways to pack the material in synthetic capsules for the delivery of genetics-based therapeutics, researchers at North Carolina State University have said.

Molecular device could identify pathogens earlier and more precisely

Researchers have developed a new technique that could enable an earlier and more accurate identification of the presence of a particular bacteria, virus or fungus even when the infection remains only in the respiratory or gastrointestinal tract.

Early user of Venter's DNA synthesizer reports saving time, money

Feedback from an early-access program for Synthetic Genomics' personal DNA workstation has started to emerge. And the initial news is positive, with a researcher at the University of California, San Francisco, reporting that the device is cutting the time and money it takes to synthesize DNA.

Researchers deploy nanoparticles that can alter packaging of DNA

Researchers at the University of Maryland at Baltimore succeeded in delivering nanoparticles into cancer cells that changed packaged DNA into circular DNA, a breakthrough that may have applications for oncology and gene-based therapy. 

Drug delivery specialist Genisphere receives an additional $2M in funding

Drug delivery specialist Genisphere announced that it has raised $2 million in private funding to advance its 3DNA nanotechnology platform through collaborations with pharma companies. The funders are existing investors including Corporate Fuel Partners.

Scientists work toward faster, easier, cheaper Ebola diagnostics

While test strips and expensive polymerase chain reaction (PCR) machines exist in the Ebola detection market, scientists are after a medical device that can detect and prevent the spread of Ebola at a low cost.

Johns Hopkins team delivers cancer-killing DNA to mouse brains with nanovehicles

Johns Hopkins researchers published a study showing they can use biodegradable nanoparticles to carry DNA to brain cancer cells. The animal study suggests that these vehicles could deliver what they call "death genes" to the cells, treating the cancer while preserving healthy brain cells in the process.

Academics dig into EMRs to discover genetic causes of disease

In the 13 years since the publication of the rough draft of the human genetic code, scientists have run thousands of genome-wide association studies to find links between DNA and disease. The work has delivered some insights, but also shown the method has limitations. Now, a new approach could avoid these flaws.

From Hollywood to healthcare: How 3-D modeling is shaping drug development

The rise of three-dimensional modeling software has changed how Hollywood studios make movies, architects plan skyscrapers and sportswear companies design running shoes. Now, the same software and design principles are changing how researchers develop drug delivery vehicles.